GNFT vs. MRK

Last updated Apr 2, 2026

Compare and contrast key facts about Genfit (GNFT) and Merck & Co., Inc. (MRK).

Performance

GNFT vs. MRK - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Genfit (GNFT) and Merck & Co., Inc. (MRK). The values are adjusted to include any dividend payments, if applicable.

GNFT vs. MRK - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
GNFT Genfit	0.00%	30.55%	-3.51%	-12.28%	-12.22%	4.17%	-75.88%	-10.24%
MRK Merck & Co., Inc.	15.65%	9.79%	-6.26%	1.01%	49.42%	1.75%	-7.20%	12.77%

Fundamentals

Market Cap GNFT : $241.46M MRK : $300.65B
EPS GNFT : -$0.33 MRK : $7.30
PS Ratio GNFT : 2.07 MRK : 4.65
PB Ratio GNFT : 4.60 MRK : 5.79
Total Revenue (TTM) GNFT : $116.80M MRK : $65.01B
Gross Profit (TTM) GNFT : $122.47M MRK : $52.98B
EBITDA (TTM) GNFT : -$1.40M MRK : $28.80B

Returns By Period

GNFT

• 1D: 0.00%
• 1M: 0.00%
• YTD: 0.00%
• 6M: 25.97%
• 1Y: 37.62%
• 3Y*: 5.76%
• 5Y*: 1.15%
• 10Y*: —

MRK

• 1D: 0.46%
• 1M: 0.27%
• YTD: 15.65%
• 6M: 36.22%
• 1Y: 43.74%
• 3Y*: 7.58%
• 5Y*: 13.97%
• 10Y*: 12.36%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

GNFT vs. MRK — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GNFT

GNFT Risk / Return Rank: 65
GNFT Sharpe Ratio Rank: 68
GNFT Sortino Ratio Rank: 66
GNFT Omega Ratio Rank: 68
GNFT Calmar Ratio Rank: 59
GNFT Martin Ratio Rank: 63

MRK

MRK Risk / Return Rank: 81
MRK Sharpe Ratio Rank: 84
MRK Sortino Ratio Rank: 80
MRK Omega Ratio Rank: 78
MRK Calmar Ratio Rank: 82
MRK Martin Ratio Rank: 82

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GNFT vs. MRK - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Genfit (GNFT) and Merck & Co., Inc. (MRK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	GNFT	MRK	Difference
Sharpe ratio Return per unit of total volatility	0.80	1.52	-0.72
Sortino ratio Return per unit of downside risk	1.47	2.17	-0.70
Omega ratio Gain probability vs. loss probability	1.21	1.28	-0.06
Calmar ratio Return relative to maximum drawdown	0.85	2.52	-1.67
Martin ratio Return relative to average drawdown	2.49	6.65	-4.16
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

GNFT vs. MRK - Sharpe Ratio Comparison

The current GNFT Sharpe Ratio is 0.80, which is lower than the MRK Sharpe Ratio of 1.52. The chart below compares the historical Sharpe Ratios of GNFT and MRK, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	GNFT	MRK	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.80	1.52	-0.72
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.02	0.60	-0.58
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.55	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.29	0.49	-0.78

Correlation

The correlation between GNFT and MRK is 0.07, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

GNFT vs. MRK - Dividend Comparison

GNFT has not paid dividends to shareholders, while MRK's dividend yield for the trailing twelve months is around 2.75%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
GNFT Genfit	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
MRK Merck & Co., Inc.	2.75%	3.12%	3.14%	2.72%	2.52%	3.41%	3.03%	2.48%	2.60%	3.36%	3.14%	3.43%

Drawdowns

GNFT vs. MRK - Drawdown Comparison

The maximum GNFT drawdown since its inception was -89.42%, which is greater than MRK's maximum drawdown of -68.61%. Use the drawdown chart below to compare losses from any high point for GNFT and MRK.

Drawdown Indicators

	GNFT	MRK	Difference
Max Drawdown Largest peak-to-trough decline	-89.42%	-68.61%	-20.81%
Max Drawdown (1Y) Largest decline over 1 year	-23.50%	-15.16%	-8.34%
Max Drawdown (5Y) Largest decline over 5 years	-57.11%	-43.44%	-13.67%
Max Drawdown (10Y) Largest decline over 10 years	—	-43.44%	—
Current Drawdown Current decline from peak	-81.09%	-3.60%	-77.49%
Average Drawdown Average peak-to-trough decline	-74.46%	-18.88%	-55.58%
Ulcer Index Depth and duration of drawdowns from previous peaks	12.08%	5.94%	+6.14%

Volatility

GNFT vs. MRK - Volatility Comparison

The current volatility for Genfit (GNFT) is 0.00%, while Merck & Co., Inc. (MRK) has a volatility of 5.70%. This indicates that GNFT experiences smaller price fluctuations and is considered to be less risky than MRK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	GNFT	MRK	Difference
Volatility (1M) Calculated over the trailing 1-month period	0.00%	5.70%	-5.70%
Volatility (6M) Calculated over the trailing 6-month period	36.01%	18.76%	+17.25%
Volatility (1Y) Calculated over the trailing 1-year period	63.88%	29.07%	+34.81%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	62.02%	23.30%	+38.72%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	68.97%	22.68%	+46.29%

Financials

GNFT vs. MRK - Profitability Comparison

The chart below illustrates the profitability comparison between Genfit and Merck & Co., Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

GNFT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Genfit reported a gross profit of 35.54M and revenue of 35.54M. Therefore, the gross margin over that period was 100.0%.

MRK - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Merck & Co., Inc. reported a gross profit of 15.20B and revenue of 16.40B. Therefore, the gross margin over that period was 92.7%.

GNFT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Genfit reported an operating income of 76.00K and revenue of 35.54M, resulting in an operating margin of 0.2%.

MRK - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Merck & Co., Inc. reported an operating income of 8.74B and revenue of 16.40B, resulting in an operating margin of 53.3%.

GNFT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Genfit reported a net income of -9.96M and revenue of 35.54M, resulting in a net margin of -28.0%.

MRK - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Merck & Co., Inc. reported a net income of 2.96B and revenue of 16.40B, resulting in a net margin of 18.1%.